Skip to Content
Merck
  • Protective effects of primary neural stem cell treatment in ischemic stroke models.

Protective effects of primary neural stem cell treatment in ischemic stroke models.

Experimental and therapeutic medicine (2018-09-07)
Xiaowen Yu, Xiaoqing Wang, Shuxiong Zeng, Xiping Tuo
ABSTRACT

Strokes are a major cause of neurological disability. Stem cell replacement therapy is a potential novel strategy of treating patients that have experienced strokes. The present study examined the protective role of neural stem cell (NSC) administration in oxygen-glucose deprivation (OGD) injury and ischemic stroke animal models. Primary cultured embryonic NSCs and brain microvascular endothelial cells were indirectly co-cultured for in vitro testing. A rat model of embolic middle cerebral artery occlusion (MCAO) was used to assess the morphological and functional changes that occur following treatment with NSCs. The role of the phosphoinositide 3-kinase/protein kinase b/glycogen synthase kinase 3β (PI3K/Akt/GSK-3β) signaling pathway in the neuroprotective effects of NSC treatment was also determined. It was demonstrated in vivo and in vitro that NSC administration may attenuate the brain injury caused by stroke. Furthermore, the results suggest that activation of PI3k/Akt/GSK-3β signaling pathway serves a role in attenuating OGD injury. Inflammation, synaptic remodeling and autophagy may be improved following NSC treatment and behavioral testing suggests that treatment with NSCs improves functional recovery in rats following MCAO.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ANTI-LC3 (APG8A) (N-TERM) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-GFAP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
ANTI-BECLIN 1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution